JP2023552383A5 - - Google Patents

Info

Publication number
JP2023552383A5
JP2023552383A5 JP2023533889A JP2023533889A JP2023552383A5 JP 2023552383 A5 JP2023552383 A5 JP 2023552383A5 JP 2023533889 A JP2023533889 A JP 2023533889A JP 2023533889 A JP2023533889 A JP 2023533889A JP 2023552383 A5 JP2023552383 A5 JP 2023552383A5
Authority
JP
Japan
Prior art keywords
peptide
pharmaceutical composition
terminus
cancer
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552383A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/061886 external-priority patent/WO2022120226A1/en
Publication of JP2023552383A publication Critical patent/JP2023552383A/ja
Publication of JP2023552383A5 publication Critical patent/JP2023552383A5/ja
Pending legal-status Critical Current

Links

JP2023533889A 2020-12-04 2021-12-03 ペプチド受容体放射性核種療法 Pending JP2023552383A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121762P 2020-12-04 2020-12-04
US63/121,762 2020-12-04
PCT/US2021/061886 WO2022120226A1 (en) 2020-12-04 2021-12-03 Peptide receptor radionuclide therapy

Publications (2)

Publication Number Publication Date
JP2023552383A JP2023552383A (ja) 2023-12-15
JP2023552383A5 true JP2023552383A5 (https=) 2024-12-05

Family

ID=81853616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533889A Pending JP2023552383A (ja) 2020-12-04 2021-12-03 ペプチド受容体放射性核種療法

Country Status (9)

Country Link
US (1) US20240131206A1 (https=)
EP (1) EP4255891A4 (https=)
JP (1) JP2023552383A (https=)
KR (1) KR20230117581A (https=)
CN (1) CN116829541A (https=)
AU (1) AU2021390552A1 (https=)
CA (1) CA3203175A1 (https=)
MX (1) MX2023006483A (https=)
WO (1) WO2022120226A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025160502A1 (en) 2024-01-26 2025-07-31 The Regents Of The University Of California Peptide receptor radionuclide therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282057A3 (en) * 1987-03-11 1990-03-07 The Board Of Regents Of The University Of Michigan Chemo-radio-immuno-conjugates
MX340566B (es) * 2007-03-27 2016-07-14 Radiomedix Inc Composiciones para formacion de imagen objetivo y terapia.
US20120015899A1 (en) * 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor
WO2011082191A1 (en) * 2009-12-30 2011-07-07 Ge Healthcare Limited Method of using a 99mtc-labelled injection rgd compound and a [18f]-labelled rgd injection compound in external beam radiotherapy planning
CA2945945C (en) * 2014-04-15 2023-10-03 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
EP3468984A4 (en) * 2016-06-13 2020-03-11 The Regents of the University of California ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF
MX2019005742A (es) * 2016-11-23 2019-09-13 Cancer Targeted Tech Llc Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
GB201706472D0 (en) * 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
CN111032632B (zh) * 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
CN109091683B (zh) * 2018-08-10 2019-10-18 北京大学 一种用于整合素αvβ6靶向的环状多肽放射性药物及其制备方法
WO2021226432A2 (en) * 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections

Similar Documents

Publication Publication Date Title
EP3766893B1 (en) 177lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen
CN111629755A (zh) 联合放射疗法治疗癌症的粒子
Rosar et al. New horizons in radioligand therapy: 161Tb-PSMA-617 in advanced mCRPC
JP7447300B2 (ja) 放射性金属と複合するＤＺ－１－Ｌｙｓ－ＤＯＴＡコンジュゲート及び使用
US6391911B1 (en) Coadministration of lucanthone and radiation for treatment of cancer
EA020542B1 (ru) Альфа-излучающие частицы гидроксиапатита
JP2023547689A5 (https=)
JP2023552383A5 (https=)
Janssen et al. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide
Chen et al. In vivo examination of 188Re (I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer
Zulkowski et al. Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine
Wagman et al. Adjuvant therapy for pancreatic cancer: current treatment approaches and future challenges
Sano et al. In vivo evaluation of a radiogallium-labeled bifunctional radiopharmaceutical, Ga-DOTA-MN2, for hypoxic tumor imaging
Riva et al. Radioimmunotherapy of gastrointestinal cancer and glioblastomas
McCubrey et al. TP53 gene status can promote sensitivity and resistance to chemotherapeutic drugs and small molecule signal transduction inhibitors
Kolagatla et al. Colorectal adenocarcinoma metastasis to the hard palate: An uncommon site of metastasis for a common malignancy
Liu et al. Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model
Jeekel Adjuvant or neoadjuvant therapy for pancreatic carcinoma?
Yin et al. A novel CXCR4-targeted peptide for SPECT/CT imaging in tumor
KR20230117581A (ko) 펩티드 수용체 방사성 핵종 요법
CN118267494B (zh) 一种镭-224标记的金属有机框架纳米药物及其制备方法与应用
Sartor et al. Stromal targeted therapy in bone metastatic prostate cancer: promise delivered
Prieto European Association of Nuclear Medicine–35th Annual Congress. Barcelona–October 15-19, 2022
Behera et al. Ifosfamide containing regimen for non-small cell lung cancer
JP2025502955A (ja) 抗体内包金属フラーレン複合体及びその使用